Myomo Announces Free Screening Days in Over 20 Cities Nationwide
May 02 2018 - 8:00AM
Business Wire
Screenings Offer Free, Convenient Hands-on
Evaluations of MyoPro® Powered Brace
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the
“Company”), a commercial stage medical robotics
company, announces a nationwide program of free screening days
to be held in collaboration with its Centers of Excellence, other
orthotics and prosthetics practices and its rehabilitation therapy
partners.
Myomo and its partners will offer potential users a convenient
chance to be evaluated by clinical specialists and to examine a
MyoPro powered brace for themselves to determine if MyoPro might
help them overcome upper-limb paralysis caused by stroke, brachial
plexus injury or other neuromuscular disease or injury.
During May, free open screening clinics are planned for Boston;
Hartford, Conn.; New York City; Livonia, Madison Heights, Ann
Arbor, Grand Rapids, Grand Blanc and Detroit, Mich.; Chicago;
Milwaukee; Cincinnati, Cleveland and Columbus, Ohio; Salt Lake
City; and San Francisco. Screenings at additional locations are
planned for June.
Exact dates and locations, more information and no-cost, no
obligation registration may be found at
www.myomo.com/screening.
This nationwide rollout of the screening program follows a
successful pilot screening program at Geauga Rehabilitation
Engineering (GRE), a Myomo Center of Excellence partner, during the
first quarter of 2018 in Cleveland, Columbus, Cincinnati and
Detroit.
“Many individuals with a paralyzed arm and hand after a stroke
or injury are told they’ll never use that limb again for the rest
of their lives,” said Cliff Conneighton, Myomo’s Chief Marketing
Officer. “With our MyoPro powered arm brace, many are able to
regain movement and restore functional ability so they can return
to work, feed themselves, and perform daily living tasks. We are
launching this screening campaign to educate and assist more
individuals, families, physicians and therapists about the benefit
of the MyoPro myoelectric orthosis.”
Most commercial healthcare plans, multiple Medicaid plans,
workers’ compensation and Medicare Advantage plans have covered the
device based on medical necessity and the potential to reduce
healthcare costs. Eligible veterans may receive a MyoPro through
their local VA Medical Center.
About MyomoMyomo, Inc. is a commercial stage medical
robotics company that offers expanded mobility for those suffering
from neurological disorders and upper limb paralysis. Myomo
develops and markets the MyoPro product line. MyoPro is a powered
upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering
from CVA stroke, brachial plexus injury, traumatic brain or spinal
cord injury, ALS or other neuromuscular disease or injury. It is
currently the only marketed device that, sensing a patient’s own
EMG signals through non-invasive sensors on the arm, can
restore an individual’s ability to perform activities of daily
living, including feeding themselves, carrying objects and doing
household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. For more information, please
visit www.myomo.com.
Forward Looking StatementsThis press release contains
forward-looking statements regarding the Company's future business
expectations, which are subject to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are only predictions and may differ
materially from actual results due to a variety of factors. Our
actual results could differ materially from those anticipated in
these forward looking statements for many reasons, including,
without limitation, risks related to regulatory approval and market
acceptance of our products, and the other risk factors contained in
our filings made with the Securities and Exchange Commission.
More information about factors that potentially could affect
Myomo's financial results is included in Myomo's filings with
the Securities and Exchange Commission. The Company cautions
readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date made. The Company
disclaims any obligation subsequently to revise any forward-looking
statements to reflect events or circumstances after the date of
such statements or to reflect the occurrence of anticipated or
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180502005469/en/
For Myomo:ir@myomo.comorInvestor Relations:PCG
AdvisoryVivian Cervantes,
646-863-6274vivian@pcgadvisory.comorPublic
Relations:GreenoughRachel Robbins,
617-275-6521rrobbins@greenough.biz
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024